Corporate News
Gallantt Ispat Limited (GALLANTT.NS) experienced a decline of 5.56 % during a 24‑hour period ending at 05:02 PM Central Europe on Friday 23 Feb 2026. The current trading price on major exchanges is approximately INR 541.85.
The company’s market statistics are as follows:
- Shares outstanding: 241.3 million
- Market capitalization: INR 1.7 billion
- Volume traded in last 24 h: INR 719.4 million
- Year‑to‑date performance: –1.03 % since the end of last month
- 200‑day simple moving average: INR 623.65
- 52‑week high: INR 948 (16 Apr 2026)
- 52‑week low: INR 496.25 (18 Dec 2025)
Financial Results for the Quarter and Half‑Year Ending 30 Sep 2026
Gallantt Ispat Limited has released unaudited financial results for the quarter and half‑year ending 30 September 2026. Key highlights include:
- Expansion of revenue streams across multiple business segments.
- Increase in earnings before interest and taxes, indicating improved operating efficiency.
- Higher net profit compared with the same period a year earlier.
- The board has authorized publication of these results in leading newspapers.
- The company’s compliance officer has confirmed the release.
The data suggest that Gallantt Ispat’s profitability and revenue base are strengthening in the current fiscal period.
Related Stock Performance (Last 24 Hours)
| Ticker | Recent Move | Current Price | Market Cap | P/E Ratio |
|---|---|---|---|---|
| LASTMILE.BO | +0.2 % | INR 4.94 | INR 2 billion | 16.47 |
| ONESOURCE.NS | +1.53 % | INR 1,334.1 | INR 2 billion | – |
| VAARAD.BO | –4 % | INR 7.47 | INR 2 billion | – |
| ADCOUNTY.BO | –4.95 % | INR 75 | INR 2 billion | 9.89 |
| ARCHIDPLY.NS | –2.11 % | INR 92.56 | INR 2 billion | 15.37 |
Additional Context – Dr. Reddy’s Laboratories
On 23 Oct 2026, Dr. Reddy’s Laboratories announced the launch of two new generic semaglutide products, Obeda Pro and Obeda Plus, following a supply disruption of its original Obeda injectable. The disruption was caused by an impurity discovered in the active ingredient, leading to a July recall and an anticipated discontinuation of the original product. The new formulations are manufactured by a different contract manufacturer and are offered in various dose strengths. Analysts view the swift pivot as a strategy to preserve market share in a competitive Indian semaglutide market and to mitigate supply‑chain vulnerabilities in a rapidly growing therapeutic segment.
